Subgenomic RNA and Limited Cross-Reactive Neutralising Antibodies Point to Potential Improvements in SARS-CoV-2 Clinical Handling
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26072948 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Carlos Davina-Nunez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), 36312 Vigo, Spain. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, SARS-CoV-2, COVID-19, Antibodies, Viral. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Axencia Galega para a Xestión do Coñecemento en Saúde, Axencia Galega de Innovacion, Conselleria de Sanidade, Galicia.
Abstract (Originalsprache)
The current clinical management of SARS-CoV-2 disease control and immunity may be not optimal anymore. Reverse transcription polymerase chain reaction (RT-PCR) of genomic viral RNA is broadly used for diagnosis, even though the virus may still be detectable when it is already non-infectious. Regarding serology, commercial assays mostly still rely on ancestral spike detection despite significant changes in the genetic sequence of the current circulating variants. We followed a group of 105 non-vaccinated individuals, measuring their viral shedding until negativity and antibody response up to six months. The mean viral detection period until a negative RT-PCR result was 2.2 weeks when using subgenomic RNA-E as a detection target, and 5.2 weeks when using genomic RNA as a detection target. Our neutralising antibody results suggest that, when challenged against a variant different from the variant of first exposure, commercial immunoassays are suboptimal at predicting the neutralising capacity of sera. Additionally, anti-Alpha and anti-Delta antibodies showed very low cross-reactivity between variants. This study provides insights into viral shedding and immune response in pre-Omicron variants like Alpha and Delta, which have been understudied in the published literature. These conclusions point to potential improvements in the clinical management of SARS-CoV-2 cases in order to organise vaccination campaigns and select monoclonal antibody treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), 36312 Vigo, Spain.
- Faculty of Biology, Universidade de Vigo, 36310 Vigo, Spain.
- Microbiology Department, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, 36312 Vigo, Spain.
- Virology and Pathogenesis Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), 36312 Vigo, Spain.
- Infectious Disease Unit, Internal Medicine Department, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, 36312 Vigo, Spain.
- Preventive Medicine Department, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, 36312 Vigo, Spain.
ORCID-Profile: Carlos Davina-Nunez, Sonia Perez-Castro, Jorge Julio Cabrera-Alvargonzalez, Sergio Silva-Bea, Alexandre Perez-Gonzalez, Benito Regueiro-Garcia
Förderung
- Axencia Galega para a Xestión do Coñecemento en Saúde
- Axencia Galega de Innovacion
- Conselleria de Sanidade, Galicia
- Galician Innovation Agency
- Consellería de Sanidade, Galicia, Spain
Zitieren
APA
Davina-Nunez, C., Perez-Castro, S., Cabrera-Alvargonzalez, J. J., Gonzalez-Alonso, E., Silva-Bea, S., Rodriguez-Perez, M., Figueroa-Lamas, M. D. P., Perez-Gonzalez, A., Del Campo, V., Rojas, A., Mendoza, J., & Regueiro-Garcia, B. (2025). Subgenomic RNA and Limited Cross-Reactive Neutralising Antibodies Point to Potential Improvements in SARS-CoV-2 Clinical Handling. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26072948
Vancouver
Davina-Nunez C, Perez-Castro S, Cabrera-Alvargonzalez JJ, Gonzalez-Alonso E, Silva-Bea S, Rodriguez-Perez M, et al. Subgenomic RNA and Limited Cross-Reactive Neutralising Antibodies Point to Potential Improvements in SARS-CoV-2 Clinical Handling. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26072948
BibTeX
@article{DavinaNunez2025,
author = {Davina-Nunez, Carlos and Perez-Castro, Sonia and Cabrera-Alvargonzalez, Jorge Julio and Gonzalez-Alonso, Elena and Silva-Bea, Sergio and Rodriguez-Perez, Miriam and Figueroa-Lamas, Maria Del Pilar and Perez-Gonzalez, Alexandre and Del Campo, Victor and Rojas, Almudena and Mendoza, Joaquin and Regueiro-Garcia, Benito},
title = {Subgenomic RNA and Limited Cross-Reactive Neutralising Antibodies Point to Potential Improvements in SARS-CoV-2 Clinical Handling},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26072948}
}
EUVIMED